Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma

Cancer Research

Volumn 63, Issue 5, 2003, Pages 965-971

  Roychowdhury, Sameek ^a   Peng, Ruoqi ^a   Baiocchi, Robert A ^a   Bhatt, Darshna ^a   Vourganti, Srinivas ^a   Grecula, John ^a   Gupta, Nilendu ^a   Eisenbeis, Charles F ^a,b   Nuovo, Gerard J ^a   Yang, Weilian ^a   Schmalbrock, Petra ^a   Ferketich, Amy ^a   Moeschberger, Melvin ^a,b   Porcu, Pierluigi ^a   Barth, Rolf F ^a,b   Caligiuri, Michael A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; GENE EXPRESSION; IMMUNE DEFICIENCY; LYMPHOBLAST; MALE; MOUSE; NONHUMAN; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RAT;

ANIMALS; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; EPSTEIN-BARR VIRUS INFECTIONS; GANCICLOVIR; HERPESVIRUS 4, HUMAN; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RATS; RNA, MESSENGER; THYMIDINE KINASE; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZIDOVUDINE;

EID: 0037374285     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. MacMahon, E. M., Glass, J. D., Hayward, S. D., Mann, R. B., Becker, P. S., Charache, P., McArthur, J. C., and Ambinder, R. F. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet, 338: 969-973, 1991.
2. DeAngelis, L. M. Primary central nervous system lymphoma. Curr. Opin. Neurol. 12: 687-691, 1999.
3. Schabet, M. Epidemiology of primary CNS lymphoma. J. Neurooncol., 43: 199-201, 1999.
4. Penn, I., and Porat, G. Central nervous system lymphomas in organ allograft recipients. Transplantation (Baltimore), 59: 240-244, 1995.
5. Khoo, V. S., and Liew, K. H. Acquired immunodeficiency syndrome-related primary cerebral lymphoma. Clin. Oncol., 11: 6-14, 1999.
6. Preiksaitis, J. K., and Keay, S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin. Infect. Dis., 33: S38-S46, 2001.
7. Abrey, L. E., Yahalom, J., and DeAngelis, L. M. Treatment for primary CNS lymphoma: the next step. J. Clin. Oncol., 18: 3144-3150, 2000.
8. Phan, T. G., O'Neill, B. P., and Kurtin, P. J. Posttransplant primary CNS lymphoma. J. Neuro-Oncol., 2: 229-238, 2000.
9. Herrlinger, U., Schabet, M., Brugger, W., Kortmann, R. D., Kanz, L., Bamberg, M., Dichgans, J., and Weller, M. Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment. Cancer (Phila.), 91: 130-135, 2001.
10. Tanner, J. E., and Alfieri, C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression. EBV, and the immune system in disease pathogenesis. Transpl. Infect. Dis., 3: 60-69, 2001.
11. Mentzer, S. J., Perrine, S. P., and Faller, D. V. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl. Infect. Dis., 3: 177-185, 2001.
12. Littler, E., Zeuthen, J., McBride, A. A., Trost Sorensen, E., Powell, K. L., Walsh-Arrand, J. E., and Arrand, J. R. Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J., 5: 1959-1966, 1986.
13. Littler, E., and Arrand, J. R. Characterization of the Epstein-Barr virus-encoded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems. J. Virol., 62: 3892-3895, 1988.
14. Moore, S. M., Cannon, J. S., Tanhehco, Y. C., Hamzeh, F. M., and Ambinder, R. F. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob. Agents Chemother., 45: 2082-2091, 2001.
15. Chung, Y. L., Lee, Y. H., Yen, S. H., and Chi, K. H. A novel approach for nasopharyngeal carcinoma treatment uses phenylbutyrate as a protein kinase C modulator: implications for radiosensitization and EBV-targeted therapy. Clin. Cancer Res., 6: 1452-1458, 2000.
16. Westphal, E. M., Blackstock, W., Feng, W., Israel, B., and Kenney, S. C. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res., 60: 5781-5788, 2000.
17. Porcu, P., Eisenbeis, C. F., Pelletier, R. P., Davies, E. A., Baiocchi, R. A., Roychowdhury, S., Vourganti, S., Nuovo, G. J., Marsh, W. L., Ferketich, A. K., Henry, M. L., Ferguson, R. M., and Caligiuri, M. A. Successful treatment of post-transplant lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration. Blood, 100: 2341-2348, 2002.
18. Matthews, G. V., Bower, M., Mandatia, S., Powles, T., Nelson, M. R., and Gazzard, B. G. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood, 96: 2730-2734, 2000.
19. Baiocchi, R. A., Khatri, V. P., Lindemann, M. J., Ross, M. E., Papoff, G., Caprio, A. J., Caprio, T. V., Fenstermaker, R., Ruberti, G., Bernstein, Z. P., and Caligiuri, M. A. Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome. Blood, 90: 1737-1746, 1997.
20. Barth, R. F., Yang, W., Adams, D. M., Rotaru, J. H., Shukla, S., Sekido, M., Tjarks, W., Fenstermaker, R. A., Ciesielski, M., Nawrocky, M. M., and Coderre, J. A. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res., 62: 3159-3166, 2002.
21. Paxinos, G. The Rat Brain in Stereotaxic Coordinates, p. Iv. San Diego, CA: Academic Press, 1986.
22. Chan, T. C., Shaffer, L., Redmond, R., and Pennington, K. L. Permeation and metabolism of anti-HIV and endogenous nucleosides in human immune effector cells. Biochem. Pharmacol., 46: 273-278, 1993.
23. Klein, J. P., and Moeschberger, M. L. Survival Analysis: Techniques for Censored and Truncated Data, pp. 278-82, New York: Springer, 1997.
24. Barth, R. F., and Moeschberger, M. L. Gene Therapy for Neurological Disorders and Brain Tumors, pp. 321-24. Totowa, NJ: Totowa Press, 1998.
25. Camilleri-Broet, S., Feuillar, D. J., Bourgeois, C., Seeilhean, D., Hauw, J., and Raphael, M. High expression of latent membrane protein 1 of Epstein-Barr virus and BCL-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas. Blood, 85: 432-435, 1995.
26. Cazaux, C., Tiraby, M., Loubiere, L., Haren, L., Klatzmann, D., and Tiraby, G. Phosphorylation and cytotoxicity of therapeutic nucleoside analogues: a comparison of α and γ herpesvirus thymidine kinase suicide genes. Cancer Gene Ther., 5: 83-91, 1998.
27. Morison, L. The global epidemiology of HIV/AIDS. Br. Med. Bull., 58: 7-18, 2001.
28. Abrey, L. E., DeAngelis, L. M., and Yahalom, J. Long-term survival in primary CNS lymphoma. J. Clin. Oncol., 16: 859-863, 1998.
29. DeAngelis, L. M. Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J. Neurooncol., 43: 249-257, 1999.
30. Barth, R. F. Rat brain tumor models in experimental neuro-oncology: the 9L. C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neurooncol., 36: 91-102, 1998.
31. Gustafson, E. A., Chillemi, A. C., Sage, D. R., and Fingeroth, J. D. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob. Agents Chemother., 42: 2923-2931, 1998.
32. Marschall, M., Stein-Gerlach, M., Freitag, M., Kupfer, R., van den Bogaard, M., and Stamminger, T. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J. Gen. Virol., 83: 1013-1023, 2002.
33. Raez, L., Cabral, L., Cai, J., Landy, H., Sfakianakis, G., Byrne, G. J., Hurley, J., Scerpella, E., Jayaweera, D., and Harrington, W. J. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res. Hum. Retroviruses. 15: 713-719, 1999.
34. Mentzer, S. J., Fingeroth, J., Reilly, J. J., Perrine, S. P., and Faller, D. V. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol. Dis., 24: 114-123, 1998.
35. Faller, D. V., Mentzer, S. J., and Perrine, S. P. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr. Opin. Oncol., 13: 360-367, 2001.